Jun. 20 2024
Source Page: Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention ProgrammeFound: hyperactivity disorder (ADHD) –intellectual disabilities Studies suggest that children of mothers with epilepsy
Found: Sativex – anecdotal evidence surrounding the use of cannabis to treat epilepsy resulted in a change
Asked by: Julian Sturdy (Conservative - York Outer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help support people living with epilepsy.
Answered by Will Quince
The majority of health services for people with epilepsy are commissioned locally by integrated care boards (ICBs). ICBs are best placed to make decisions regarding the provision of health services to their local population, including for the treatment of epilepsy, subject to local prioritisation and funding.
At a national level, there are several initiatives supporting service improvement for those with epilepsy, including NHS England’s Neuroscience Service Transformation Programme and RightCare Epilepsy Toolkit.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Medicines and Healthcare products Regulatory Agency on (a) its advice on prescribing and (b) the side effects of gabapentin.
Answered by Andrew Stephenson
Gabapentin is authorised for the treatment of some forms of epilepsy, as well as peripheral neuropathic pain. The product information for gabapentin, approved by the Medicines and Healthcare products Regulatory Agency (MHRA), provides information to support the prescribing of the medication including recommendations for dose, duration of use, as well as gradual reduction when stopping. The product information includes warnings about possible side effects.
The MHRA continuously monitors the safety of gabapentin and ensures the product information reflects what is known about the medicine and its side effects.
Feb. 10 2012
Source Page: Table showing the number of apprenticeship programme starts for learning difficulty and/or disability for the years 2006/07 to 2010/11. 1 p.Found: Disabilities350.0-500.0-1370.00.006077647959138273890.0-410.0-610.0-Other Medical Condition (For Example Epilepsy
Jun. 20 2024
Source Page: Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention ProgrammeFound: deficit hyperactivity disorder and intellectual disabilities compared with babies born to women without epilepsy
Mentions:
1: Baroness Ramsey of Wall Heath (Lab - Life peer) I have seen for myself, through countless conversations with youngsters suffering from epilepsy, just - Speech Link
Jun. 24 2008
Source Page: Options for the future of payment by results: 2008/09 to 2010/11. 110 p.Found: Centre for Epilepsy, Enlighten ΠTackling Epilepsy, Epilepsy Action, Epilepsy Bereaved, Epilepsy Connections
Asked by: Emma Hardy (Labour - Kingston upon Hull West and Haltemprice)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she is taking steps to help ensure access to ketogenic diet treatment in (a) Hull West and Hessle constituency and (b) nationally.
Answered by Andrew Stephenson
The majority of health services for people with epilepsy are commissioned locally by integrated care boards (ICBs). ICBs are best placed to make decisions regarding the provision of health services to their local population, including for the treatment of epilepsy, subject to local prioritisation and funding.
At the national level, there are a number of initiatives supporting service improvement for those with epilepsy, including NHS England’s Neuroscience Service Transformation Programme and the RightCare Epilepsy Toolkit.
The National Institute for Care Excellence (NICE) guideline on epilepsies in children, young people, and adults [NG217], published in April 2022, covers diagnosing and managing epilepsy in primary and secondary care, and referral to tertiary services. Recommendation 8.1 states that a ketogenic diet should be considered under the guidance of a tertiary epilepsy specialist for certain childhood-onset epilepsy syndromes, and for drug resistant epilepsy when other treatments have failed or are not appropriate. More information on this is available at the following link:
https://www.nice.org.uk/guidance/ng217/chapter/8-Non-pharmacological-treatments#ketogenic-diet
We expect National Health Service commissioners to take NICE guidelines into full account in designing services that meet the needs of their local populations. It is, however, important to note that NICE guidelines are not mandatory and do not override a clinician’s responsibility to make decisions appropriate to individual patients, in consultation with them and their families.